X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Biocon Ltd with Cipla - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON LTD vs CIPLA - Comparison Results

BIOCON LTD    Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON LTD CIPLA BIOCON LTD/
CIPLA
 
P/E (TTM) x 82.9 44.6 186.0% View Chart
P/BV x 7.8 3.8 204.1% View Chart
Dividend Yield % 0.2 0.3 47.3%  

Financials

 BIOCON LTD   CIPLA
EQUITY SHARE DATA
    BIOCON LTD
Mar-17
CIPLA
Mar-17
BIOCON LTD/
CIPLA
5-Yr Chart
Click to enlarge
High Rs1,162622 186.8%   
Low Rs483458 105.3%   
Sales per share (Unadj.) Rs194.6181.9 107.0%  
Earnings per share (Unadj.) Rs34.412.9 267.3%  
Cash flow per share (Unadj.) Rs48.329.3 164.6%  
Dividends per share (Unadj.) Rs1.002.00 50.0%  
Dividend yield (eoy) %0.10.4 32.8%  
Book value per share (Unadj.) Rs241.9155.7 155.4%  
Shares outstanding (eoy) m200.00804.51 24.9%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x4.23.0 142.3%   
Avg P/E ratio x23.942.0 56.9%  
P/CF ratio (eoy) x17.018.4 92.5%  
Price / Book Value ratio x3.43.5 98.0%  
Dividend payout %2.915.5 18.7%   
Avg Mkt Cap Rs m164,440434,516 37.8%   
No. of employees `0009.223.0 40.1%   
Total wages/salary Rs m7,47026,338 28.4%   
Avg. sales/employee Rs Th4,213.96,349.1 66.4%   
Avg. wages/employee Rs Th809.01,143.0 70.8%   
Avg. net profit/employee Rs Th745.2449.3 165.8%   
INCOME DATA
Net Sales Rs m38,911146,302 26.6%  
Other income Rs m1,5712,287 68.7%   
Total revenues Rs m40,482148,589 27.2%   
Gross profit Rs m9,79524,758 39.6%  
Depreciation Rs m2,77213,229 21.0%   
Interest Rs m2601,594 16.3%   
Profit before tax Rs m8,33412,222 68.2%   
Minority Interest Rs m1630-   
Prior Period Items Rs m0-70 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,6161,798 89.9%   
Profit after tax Rs m6,88110,354 66.5%  
Gross profit margin %25.216.9 148.8%  
Effective tax rate %19.414.7 131.8%   
Net profit margin %17.77.1 249.9%  
BALANCE SHEET DATA
Current assets Rs m40,47787,370 46.3%   
Current liabilities Rs m16,78333,081 50.7%   
Net working cap to sales %60.937.1 164.1%  
Current ratio x2.42.6 91.3%  
Inventory Days Days6087 68.5%  
Debtors Days Days8362 133.0%  
Net fixed assets Rs m45,073111,567 40.4%   
Share capital Rs m1,0001,609 62.2%   
"Free" reserves Rs m47,377123,645 38.3%   
Net worth Rs m48,377125,254 38.6%   
Long term debt Rs m21,08236,454 57.8%   
Total assets Rs m93,942209,532 44.8%  
Interest coverage x33.18.7 381.3%   
Debt to equity ratio x0.40.3 149.7%  
Sales to assets ratio x0.40.7 59.3%   
Return on assets %7.65.7 133.3%  
Return on equity %14.28.3 172.1%  
Return on capital %12.68.5 148.3%  
Exports to sales %034.2 0.0%   
Imports to sales %08.3 0.0%   
Exports (fob) Rs mNA50,050 0.0%   
Imports (cif) Rs mNA12,203 0.0%   
Fx inflow Rs m12,98851,066 25.4%   
Fx outflow Rs m7,89917,678 44.7%   
Net fx Rs m5,08933,388 15.2%   
CASH FLOW
From Operations Rs m6,40023,824 26.9%  
From Investments Rs m-4,985-13,127 38.0%  
From Financial Activity Rs m-1,775-13,239 13.4%  
Net Cashflow Rs m-473-2,478 19.1%  

Share Holding

Indian Promoters % 40.4 16.0 252.5%  
Foreign collaborators % 20.6 20.8 99.0%  
Indian inst/Mut Fund % 8.4 12.2 68.9%  
FIIs % 10.7 23.7 45.1%  
ADR/GDR % 0.0 1.1 -  
Free float % 19.9 26.2 76.0%  
Shareholders   109,995 161,166 68.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON LTD With:   STRIDES SHASUN LTD  ELDER PHARMA  ALEMBIC LTD  DR. DATSONS LABS  WOCKHARDT LTD.  

Compare BIOCON LTD With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Chart Modest Gains(RoundUp)

Global financial markets ended the holiday shortened week with modest gains. The rally put behind days of decline as concerns regarding swift interest rates hikes were put to ease.

Related Views on News

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Cipla: Extraordinary Income Boosts Net Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

Proceeds from the sale of the South African animal business bolstered Cipla's net profits for the quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON LTD SHARE PRICE


Feb 23, 2018 (Close)

TRACK BIOCON LTD

  • Track your investment in BIOCON LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

BIOCON LTD - NOVARTIS COMPARISON

COMPARE BIOCON LTD WITH

MARKET STATS